Serum antibody titers against hepatitis C virus and postoperative intrahepatic recurrence of hepatocellular carcinoma

Annals of Surgical Oncology

Volumn 21, Issue 5, 2014, Pages 1719-1725

  Uemura, Mamoru ^a   Sasaki, Yo ^b   Yamada, Terumasa ^c   Gotoh, Kunihito ^d   Eguchi, Hidetoshi ^a   Yano, Masahiko ^d   Ohigashi, Hiroaki ^d   Ishikawa, Osamu ^d   Imaoka, Shingi ^d  

^a OSAKA UNIVERSITY   (Japan)

^b Yao Municipal Hospital   (Japan)

^c Higashiosaka City General Hospital   (Japan)

^d OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C VIRUS ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER PROGNOSIS; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME IMMUNOASSAY; FEMALE; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER INJURY; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDY; PROTHROMBIN TIME; RISK FACTOR; UNIVARIATE ANALYSIS; BLOOD; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; FOLLOW UP; HEPACIVIRUS; HEPATITIS C; IMMUNOLOGY; ISOLATION AND PURIFICATION; LIVER NEOPLASMS; MORTALITY; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; SURVIVAL RATE; VIROLOGY;

AGED; ANTIBODIES, VIRAL; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATECTOMY; HEPATITIS C; HUMANS; LIVER NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 84898879753     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3417-4     Document Type: Article

References (26)

1. Yang JD, Roberts LR. Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am. 2010;24:899-919, viii.
2. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752-63. (Pubitemid 351615415)
3. Sasaki Y, Yamada T, Tanaka H, et al. Risk of recurrence in a long-term follow-up after surgery in 417 patients with hepatitis B- or hepatitis C-related hepatocellular carcinoma. Ann Surg. 2006;244:771-80. (Pubitemid 44629952)
4. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27:1485-91.
5. Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet. 2009;373:614-6.
6. Tang ZY, Ye SL, Liu YK, et al. A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:187-96. (Pubitemid 38553626)
7. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118-27.
8. Belghiti J, Panis Y, Farges O, et al. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg. 1991;214:114-7.
9. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med. 1999;131:174-81. (Pubitemid 29364999)
10. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995;346:1051-5.
11. Tung HD, Lu SN, Lee CM, et al. Antiviral treatment responses in patients with chronic hepatitis C virus infection evaluated by a third generation anti-hepatitis C virus assay. J Viral Hepat. 2002;9:304-8. (Pubitemid 36002466)
12. Hara M, Mori M, Hara T, et al. Risk of developing hepatocellular carcinoma according to the titer of antibody to hepatitis C virus. Hepatogastroenterology. 2001;48:498-501. (Pubitemid 32391599)
13. Jwo SC, Chiu JH, Chau GY, et al. Risk factors linked to tumor recurrence of human hepatocellular carcinoma after hepatic resection. Hepatology. 1992;16:1367-71.
14. Sakon M, Umeshita K, Nagano H, et al. Clinical significance of hepatic resection in hepatocellular carcinoma: Analysis by disease-free survival curves. Arch Surg. 2000;135:1456-9.
15. Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200-7. (Pubitemid 36169630)
16. Makuuchi M. The general rules for the clinical and pathological study of primary liver cancer. 4th ed. Tokyo: Kanehara; 2000.
17. Liver Cancer Study Group of Japan (LCSGJ). The general rules for the clinical and pathological study of primary liver cancer. 5th ed. Tokyo: Kanehara 2008.
18. Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994;19:1513-20. (Pubitemid 24166476)
19. Tounou S, Hino K. Clinical and pathological study of asymptomatic hepatitis C virus (HCV) carriers. Ann Intern Med. 1998;132:517-24.
20. Shimada M, Hasegawa H, Gion T, et al. Risk factors of the recurrence of hepatocellular carcinoma originating from residual cancer cells after hepatectomy. Hepatogastroenterology. 1999;46:2469-75. (Pubitemid 29454124)
21. Schvarcz R, Ando Y, Sonnerborg A, Weiland O. Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience. J Hepatol. 1995;23(Suppl 2):17-21. (Pubitemid 26048738)
22. Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology. 2002;35:1002-9. (Pubitemid 34453997)
23. Lin C, Kwong AD, Perni RB. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets. 2006;6:3-16. (Pubitemid 43796632)
24. Lin C, Lin K, Luong YP, et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem. 2004;279:17508-14. (Pubitemid 38560514)
25. Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med. 2000;132:517-24. (Pubitemid 30171890)
26. Mazzaferro V, Romito R, Schiavo M, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 2006;44:1543-54. (Pubitemid 44970357)